Research Topics
Species | Lee EllisSummaryAffiliation: The University of Texas Country: USA Publications
Research Grants
| Collaborators
|
Detail Information
Publications
Role of angiogenesis inhibitors in cancer treatmentL M Ellis
Department of Surgical Oncology, The University of Texas M D Anderson Cancer Center, Houston 77030, USA
Oncology (Williston Park) 15:39-46. 2001..Understanding the basic principles that drive tumor angiogenesis will lead to the development of therapies that will likely prolong survival without the toxicity associated with standard chemotherapy...- Preclinical data targeting vascular endothelial growth factor in colorectal cancerLee M Ellis
Department of Surgical Oncology, Box 444, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030 4009, USA
Clin Colorectal Cancer 4:S55-61. 2004..Understanding the mechanisms of the role of VEGF in CRC angiogenesis and the effect of anti-VEGF therapy on the tumor vasculature will allow oncologists to optimize therapeutic regimens targeting VEGF and its receptors... - BevacizumabLee M Ellis
University of Texas MD Anderson Cancer Center, Houston 77230 1402, USA
Nat Rev Drug Discov . 2005..It is the first approved agent to target tumour angiogenesis... - The role of neuropilins in cancerLee M Ellis
University of Texas M D Anderson Cancer Center, Unit 444, P O Box 301402, Houston, TX 77230 1402, USA
Mol Cancer Ther 5:1099-107. 2006..The therapeutic implications of these data are far-reaching and suggest that neuropilin-targeted interventions may be useful as a component of antineoplastic therapy... - Mechanisms of action of bevacizumab as a component of therapy for metastatic colorectal cancerLee M Ellis
Department of Surgical Oncology, University of Texas M D Anderson Cancer Center, Houston, Texas 77230, USA
Semin Oncol 33:S1-7. 2006..However, bevacizumab has been shown to increase the response rates with chemotherapy in almost all tumor types studied in phase III trials... - Antiangiogenic therapy at a crossroads: clinical trial results and future directionsLee M Ellis
Department of Surgery, University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Blvd, Box 444, Houston, TX 77030-4009, USA
J Clin Oncol 21:281s-283s. 2003 - VEGF-targeted therapy: mechanisms of anti-tumour activityLee M Ellis
Department of Surgical Oncology, Unit 444, University of Texas M D Anderson Cancer Center, PO Box 301402, Houston, Texas 77230 1402, USA
Nat Rev Cancer 8:579-91. 2008..A better understanding of these mechanisms will lead to future advances in the use of these agents in the clinic... - Synopsis of angiogenesis inhibitors in oncologyLee M Ellis
Department of Surgical Oncology, The University of Texas, M D Anderson Cancer Center, Houston 77030 4009, USA
Oncology (Williston Park) 16:14-22. 2002..Nevertheless, the understanding of the basic principles that drive tumor angiogenesis will lead to the development of therapies that will likely prolong survival without the toxicity associated with standard chemotherapy... - Angiopoietins and their role in colon cancer angiogenesisLee M Ellis
Department of Surgical Oncology, The University of Texas M D Anderson Cancer Center, Houston 77030 4009, USA
Oncology (Williston Park) 16:31-5. 2002..This may ultimately lead to tumor dormancy by transforming a rapidly growing tumor into an indolent tumor... - Pathways mediating resistance to vascular endothelial growth factor-targeted therapyLee M Ellis
Department of Surgical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77230 1402, USA
Clin Cancer Res 14:6371-5. 2008.... - Antiangiogenic therapy targeting factors that enhance endothelial cell survivalWenbiao Liu
Departments of Cancer Biology and Surgical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, TX 77030-4009, USA
Semin Oncol 29:96-103. 2002..Lastly, pericytes contribute to EC stabilization by cell-cell contact and/or secretion of survival factors, such as vascular endothelial growth factor. Targeting EC survival factors may provide a novel antineoplastic strategy for cancer... - Recurrence and outcomes following hepatic resection, radiofrequency ablation, and combined resection/ablation for colorectal liver metastasesEddie K Abdalla
Department of Surgical Oncology, University of Texas M. D. Anderson Cancer Center, Houston, TX, USA
Ann Surg 239:818-25; discussion 825-7. 2004..RFA alone or in combination with resection for unresectable patients does not provide survival comparable to resection, and provides survival only slightly superior to nonsurgical treatment... - Perioperative complications in patients undergoing major liver resection with or without neoadjuvant chemotherapyAlexander A Parikh
Department of Surgical Oncology, The University of Texas M.D. Anderson Cancer Center, Houston, Texas 77030, USA
J Gastrointest Surg 7:1082-8. 2003..It may therefore provide a better therapeutic option, particularly in patients with multiple colorectal metastases... - Pathologic response to preoperative chemotherapy: a new outcome end point after resection of hepatic colorectal metastasesDan G Blazer
Department of Surgical Oncology, Gastrointestinal Medical Oncology, and Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030 4009, USA
J Clin Oncol 26:5344-51. 2008..The secondary goal of the study was to identify the clinical predictors of pathologic response... - Advances in the treatment of liver tumorsSteven A Curley
The University of Texas M.D. Anderson Cancer Center, Houston, USA
Curr Probl Surg 39:449-571. 2002 - Phase I study of recombinant human endostatin in patients with advanced solid tumorsRoy S Herbst
Department of Thoracic and Head and Neck Medical Oncology, University of Texas M.D. Anderson Cancer Center, Houston, TX 77030, USA
J Clin Oncol 20:3792-803. 2002..rh-Endo pharmacokinetic profiles achieved area under the concentration-time curves associated with activity in preclinical models. Evidence of minor antitumor activity was observed and further studies are indicated... - Debunking dogma: surgery for four or more colorectal liver metastases is justifiedTimothy M Pawlik
Department of Surgical Oncology, The University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
J Gastrointest Surg 10:240-8. 2006..Certain clinicopathologic factors, including lack of response to neoadjuvant chemotherapy, were associated with a worse prognosis... - Vascular endothelial growth factor targeted therapy in the perioperative setting: implications for patient careDebashish Bose
Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77230, USA
Lancet Oncol 11:373-82. 2010.... - Vascular endothelial growth factor receptors: expression and function in solid tumorsJane S Wey
Department of Surgical Oncology, Texas M. D. Anderson Cancer Center, Houston, TX 77030, USA
Clin Adv Hematol Oncol 2:37-45. 2004..This elucidation of VEGF activity may further refine antineoplastic regimens for solid malignancies... - Oral capecitabine for the treatment of hepatocellular carcinoma, cholangiocarcinoma, and gallbladder carcinomaYehuda Z Patt
Department of Gastrointestinal Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
Cancer 101:578-86. 2004..The goal of the current study was to evaluate the efficacy and toxicity of capecitabine in patients with nonresectable hepatobiliary carcinoma... - Preoperative bevacizumab does not significantly increase postoperative complication rates in patients undergoing hepatic surgery for colorectal cancer liver metastasesSusan B Kesmodel
Department of Surgical Oncology, Cancer Biology, Biostatistics, and Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
J Clin Oncol 26:5254-60. 2008..We therefore evaluated whether neoadjuvant BV is associated with an increase in postoperative complications in patients undergoing surgery for CRC liver metastases... - Increased apoptosis in metastatic human colonic adenocarcinomasPaula M Termuhlen
Departments of Cancer Biology, Surgical Oncology, University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, Texas 77030, USA
Cancer Biol Ther 1:58-63. 2002..Our data demonstrate that the molecular events associated with acquisition of the metastatic phenotype sensitize colon cancer cells to some pro-apoptotic stimuli... - Promises and pitfalls of anti-angiogenic therapy in clinical trialsMarya F McCarty
Dept of Surgical Oncology, The University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Blvd, P.O. Box 444, Houston, TX 77030, USA
Trends Mol Med 9:53-8. 2003..Further insights into the complex process of angiogenesis are essential for the development of effective anti-angiogenic regimens... - Effect of the vascular endothelial growth factor receptor-2 antibody DC101 plus gemcitabine on growth, metastasis and angiogenesis of human pancreatic cancer growing orthotopically in nude miceChristiane J Bruns
Departments of Cancer Biology and Surgical Oncology, The University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
Int J Cancer 102:101-8. 2002..Anti-VEGF receptor-2 therapy in combination with gemcitabine may be a novel therapeutic approach for advanced pancreatic cancer... - Angiogenesis and its role in colorectal tumor and metastasis formationLee M Ellis
Departments of Surgical Oncology and Cancer Biology, University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Boulevard, Box 444, Houston, TX 77030, USA
Semin Oncol 31:3-9. 2004..This article will highlight what is known about colorectal cancer angiogenesis, and will discuss how therapy targeting VEGF may enhance the effects of chemotherapy (and radiation therapy)... - Combined anti-fetal liver kinase 1 monoclonal antibody and continuous low-dose doxorubicin inhibits angiogenesis and growth of human soft tissue sarcoma xenografts by induction of endothelial cell apoptosisLianglin Zhang
Department of Surgical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030, USA
Cancer Res 62:2034-42. 2002..Collectively, our data suggested that anti-VEGF receptor 2 in combination with continuous low-dose doxorubicin may provide a new therapeutic approach for human soft tissue sarcoma in the clinic... - Biology of angiogenesis in tumors of the gastrointestinal tractNiels Reinmuth
Department of Cancer Biology, The University of Texas M.D. Anderson Cancer Center, Houston, Texas 77030, USA
Microsc Res Tech 60:199-207. 2003..A thorough understanding of the role these factors play in the angiogenic process may lead to the development of novel therapeutic antineoplastic strategies... - Phase II trial of systemic continuous fluorouracil and subcutaneous recombinant interferon Alfa-2b for treatment of hepatocellular carcinomaYehuda Z Patt
Department of Gastrointestinal Medical Oncology and Digestive Diseases, The University of Texas M D Anderson Cancer Center, Houston, TX, USA
J Clin Oncol 21:421-7. 2003..Patients and.. - Angiopoietin-1 inhibits vascular permeability, angiogenesis, and growth of hepatic colon cancer tumorsOliver Stoeltzing
Department of Cancer Biology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
Cancer Res 63:3370-7. 2003..Thus, Ang-1 could potentially serve as an antineoplastic or anti-permeability agent for patients with metastatic colorectal cancer... - Blockade of insulin-like growth factor I receptor function inhibits growth and angiogenesis of colon cancerNiels Reinmuth
Departments of Cancer Biology, University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030, USA
Clin Cancer Res 8:3259-69. 2002..CONCLUSIONS: These studies demonstrate that the IGF ligand-receptor system plays an important role in multiple mechanisms that mediate human colon cancer growth including regulation of VEGF and angiogenesis... - Alphavbeta3 integrin antagonist S247 decreases colon cancer metastasis and angiogenesis and improves survival in miceNiels Reinmuth
Department of Cancer Biology, The University of Texas M. D. Anderson Cancer Center, Houston 77030, USA
Cancer Res 63:2079-87. 2003..The use of agents such as integrin antagonists that target multiple cell types involved in angiogenesis may be a more effective method of inhibiting angiogenesis than agents targeting only the endothelial cells... - Feasibility of adjuvant hepatic arterial infusion of chemotherapy after radiofrequency ablation with or without resection in patients with hepatic metastases from colorectal cancerCourtney L Scaife
Departments of Surgical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030, USA
Ann Surg Oncol 10:348-54. 2003..The high rate of disease recurrence in our patients indicates that novel combinations of regional and systemic therapies are needed to improve patient outcomes... - Targeting of insulin-like growth factor-I receptor with a monoclonal antibody inhibits growth of hepatic metastases from human colon carcinoma in miceTodd W Bauer
Department of Surgical Oncology, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA
Ann Surg Oncol 14:2838-46. 2007..Colorectal carcinomas (CRC) express high levels of insulin-like growth factor-I/II (IGF-I/II) and the receptor (IGF-IR). We hypothesized that selective inhibition of IGF-IR would inhibit hepatic growth of human CRC in mice... - Neuropilin-1 in human colon cancer: expression, regulation, and role in induction of angiogenesisAlexander A Parikh
Departments of Surgical Oncology and Cancer Biology, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030 4009, USA
Am J Pathol 164:2139-51. 2004..This study also suggests that EGF and mitogen-activated protein kinase signaling pathways play an important role in NRP-1 regulation in colon cancer cells... - Angiogenesis and antiangiogenic therapy of colon cancer liver metastasisOliver Stoeltzing
Department of Cancer Biology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030, USA
Ann Surg Oncol 10:722-33. 2003..This review focuses on angiogenesis in colorectal cancer metastasis formation as a target for antiangiogenic therapy, describing the experience from experimental studies and current clinical trials... - Impact of insulin-like growth factor receptor-I function on angiogenesis, growth, and metastasis of colon cancerNiels Reinmuth
Department of Cancer Biology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
Lab Invest 82:1377-89. 2002..These studies demonstrate that the IGF-IR plays an important role in multiple mechanisms that mediate the growth, angiogenesis, and metastasis of human colon cancer. IGF-IR is a valid target for the therapy of human colon cancer... - Role of class 3 semaphorins and their receptors in tumor growth and angiogenesisPuja Gaur
Departments of Surgical Oncology and Cancer Biology, The University of Texas M D Anderson Cancer Center, Houston, Texas, USA
Clin Cancer Res 15:6763-70. 2009..Herein, we briefly review (a) the role of SEMA3s in mediating tumor growth, (b) the SEMA3 receptors neuropilins and plexins, and (c) the potential competition between SEMA3s and VEGF family members for neuropilin binding... - Predictors of microvascular invasion in patients with hepatocellular carcinoma who are candidates for orthotopic liver transplantationNestor F Esnaola
Department of Surgery, The University of Texas M.D. Anderson Cancer Center, Houston, TX 77030-4009, USA
J Gastrointest Surg 6:224-32; discussion 232. 2002..3; 95% CI, 2.0 to 19.9). Tumor size and grade are strong predictors of microvascular invasion. A tumor biopsy with pathologic grading at the time of pretransplantation ablative therapy could improve selection of patients with HCC for OLT... - Activator protein 2alpha inhibits tumorigenicity and represses vascular endothelial growth factor transcription in prostate cancer cellsMaribelis Ruiz
Department of Cancer Biology, University of Texas M D Anderson Cancer Center, Houston, Texas, USA
Cancer Res 64:631-8. 2004..AP-2 acts as a tumor-suppressor gene in prostate cancer. Elucidating the molecular events resulting from loss of AP-2 in the prostate epithelium has implications for the understanding and prevention of the onset of prostate cancer... - Green tea inhibits vascular endothelial growth factor (VEGF) induction in human breast cancer cellsMaryam R Sartippour
Department of Surgery, Division of Oncology and Center for Human Nutrition, University of California, Los Angeles 90095, USA
J Nutr 132:2307-11. 2002..Inhibition of VEGF transcription appeared to be one of the molecular mechanism(s) involved in the antiangiogenic effects of green tea, which may contribute to its potential use for breast cancer treatment and/or prevention... - Synergistic activity of the SRC family kinase inhibitor dasatinib and oxaliplatin in colon carcinoma cells is mediated by oxidative stressScott Kopetz
Department of Cancer Biology, The University of Texas MD Anderson Cancer Center and Program in Cancer Biology, The University of Texas Graduate School of Biomedical Sciences at Houston, Houston, Texas 77030 4009, USA
Cancer Res 69:3842-9. 2009..These results suggest that Src inhibitors combined with oxaliplatin may have efficacy in metastatic colon cancer and may provide the first indication of a molecular phenotype that might be susceptible to such combinations... - Phase I trial evaluating the safety of bevacizumab with concurrent radiotherapy and capecitabine in locally advanced pancreatic cancerChristopher H Crane
Department of Radiation Oncology, Unit 97, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
J Clin Oncol 24:1145-51. 2006..To study the safety of bevacizumab with capecitabine-based chemoradiotherapy... - Roles of nitric oxide synthase inhibition and vascular endothelial growth factor receptor-2 inhibition on vascular morphology and function in an in vivo model of pancreatic cancerE Ramsay Camp
Department of Surgical Oncology, The University of Texas M.D. Anderson Cancer Center, Houston, Texas, USA
Clin Cancer Res 12:2628-33. 2006.... - Phase II trial of infusional fluorouracil, irinotecan, and bevacizumab for metastatic colorectal cancer: efficacy and circulating angiogenic biomarkers associated with therapeutic resistanceScott Kopetz
University of Texas MD Anderson Cancer Center Lyndon B Johnson Hospital, Harris County Hospital District, Houston, TX, USA
J Clin Oncol 28:453-9. 2010.... - Phase II trial of neoadjuvant bevacizumab, capecitabine, and radiotherapy for locally advanced rectal cancerChristopher H Crane
Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
Int J Radiat Oncol Biol Phys 76:824-30. 2010..We designed this Phase II trial to assess the efficacy and safety of the addition of bevacizumab to concurrent neoadjuvant capecitabine-based chemoradiation in locally advanced rectal cancer... - Results of a single-center experience with resection and ablation for sarcoma metastatic to the liverTimothy M Pawlik
Department of Surgical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston 77030, USA
Arch Surg 141:537-43; discussion 543-4. 2006..Patients with sarcoma liver metastasis should be evaluated by a multidisciplinary team, as recurrence is common and adjuvant therapy may prolong survival... - Effect of different types of smoking and synergism with hepatitis C virus on risk of hepatocellular carcinoma in American men and women: case-control studyManal M Hassan
Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
Int J Cancer 123:1883-91. 2008..Controlling for smoking exposure might be a prudent approach to the prevention of HCC, especially in patients with chronic viral hepatitis infections... - Chronic oxaliplatin resistance induces epithelial-to-mesenchymal transition in colorectal cancer cell linesAnthony D Yang
Department of Surgical Oncology, The University of Texas M.D. Anderson Cancer Center, Houston, Texas 77230-1402, USA
Clin Cancer Res 12:4147-53. 2006..Further understanding of the mechanisms of chemoresistance in CRC will enable improvements in chemotherapy for metastatic disease... - Simplified staging for hepatocellular carcinomaJean Nicolas Vauthey
International Cooperative Study Group on Hepatocellular Carcinoma, Department of Surgical Oncology, The University of Texas M D Anderson Cancer Center, Houston, 77030, USA
J Clin Oncol 20:1527-36. 2002..The current American Joint Committee on Cancer (AJCC) staging system for hepatocellular carcinoma (HCC) fails to stratify patients adequately with respect to prognosis... - Targeting tumor angiogenesisPuja Gaur
Department of Surgical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX, USA
Semin Oncol 36:S12-9. 2009.... - Functional significance of vascular endothelial growth factor receptors on gastrointestinal cancer cellsNikolaos A Dallas
Department of Surgical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77230 1402, USA
Cancer Metastasis Rev 26:433-41. 2007..Elucidating the function of VEGF receptors on tumor cells should help us to better understand the potential mechanisms of action of anti-VEGF therapies... - Development of biologic markers of response and assessment of antiangiogenic activity in a clinical trial of human recombinant endostatinRoy S Herbst
Department of Thoracic and Head and Neck Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX, USA
J Clin Oncol 20:3804-14. 2002..We present the initial results of a dose-finding clinical trial of recombinant human endostatin (rh-Endo) that examined potential surrogates for response to antiangiogenic therapy... - Response to preoperative chemoradiation increases the use of sphincter-preserving surgery in patients with locally advanced low rectal carcinomaChristopher H Crane
Department of Radiation Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
Cancer 97:517-24. 2003..This article investigates the relationship between objective tumor response and sphincter preservation in low rectal carcinoma patients... - Epidermal growth factor receptor in tumor angiogenesisLee M Ellis
The University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Box 444, Houston, TX 77030 4009, USA
Hematol Oncol Clin North Am 18:1007-21, viii. 2004..This article focuses on the preclinical evidence for activation of the epidermal growth factor receptor (EGFR) in promoting angiogenesis and the efficacy of anti-EGFR agents in inhibiting angiogenesis and tumor growth... - ZD6474, a vascular endothelial growth factor receptor tyrosine kinase inhibitor with additional activity against epidermal growth factor receptor tyrosine kinase, inhibits orthotopic growth and angiogenesis of gastric cancerMarya F McCarty
Department of Surgical Oncology, Unit 444, University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030-4009, USA
Mol Cancer Ther 3:1041-8. 2004..In conclusion, therapies such as ZD6474 that target two distinct aspects of tumor growth, angiogenesis and tumor cell proliferation, warrant further investigation... - Monoclonal antibodies: the foundation of therapy for colorectal cancer in the 21st century?Paulo M Hoff
Department of Gastrointestinal Medical Oncology, The University of Texas, M D Anderson Cancer Center, Houston, Texas 77030 4009, USA
Oncology (Williston Park) 18:736-41; discussion 742, 745-6. 2004.... - Is extended hepatectomy for hepatobiliary malignancy justified?Jean Nicolas Vauthey
Departments of Surgical Oncology, University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 444, Houston, TX 77030, USA
Ann Surg 239:722-30; discussion 730-2. 2004..Extended hepatectomy may be required to provide the best chance for cure of hepatobiliary malignancies. However, the procedure may be associated with significant morbidity and mortality... - Clinical and pathologic predictors of locoregional recurrence, distant metastasis, and overall survival in patients treated with chemoradiation and mesorectal excision for rectal cancerPrajnan Das
Department of Radiation Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
Am J Clin Oncol 29:219-24. 2006..To identify predictive factors for locoregional recurrence (LR), distant metastasis (DM), and overall survival (OS) in patients treated with chemoradiation and surgery for rectal cancer... - Early and late complications after radiofrequency ablation of malignant liver tumors in 608 patientsSteven A Curley
Department of Surgical Oncology, University of Texas M D Anderson Cancer Center, Houston, Texas 77030 4095, USA
Ann Surg 239:450-8. 2004..We performed this prospective analysis to determine early (within 30 days) and late (more than 30 days after) complication rates associated with hepatic tumor RFA... - HIF-1alpha, STAT3, CBP/p300 and Ref-1/APE are components of a transcriptional complex that regulates Src-dependent hypoxia-induced expression of VEGF in pancreatic and prostate carcinomasMichael J Gray
Department of Cancer Biology, The University of Texas MD Anderson Cancer Center, 1515 Holcomb Boulevard, Houston, TX 77030, USA
Oncogene 24:3110-20. 2005..These data suggest that the binding of both STAT3 and HIF-1alpha to the VEGF promoter is required for maximum transcription of VEGF mRNA following hypoxia... - Regulation of hypoxia-inducible factor-1alpha, vascular endothelial growth factor, and angiogenesis by an insulin-like growth factor-I receptor autocrine loop in human pancreatic cancerOliver Stoeltzing
Department of Cancer Biology, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030 4009, USA
Am J Pathol 163:1001-11. 2003..02). Our results suggest that autocrine activation of the IGF-IR system significantly affects VEGF expression and angiogenesis in human pancreatic cancer. Thus, IGF-IR may be a valid target in the treatment of pancreatic cancer... - Significant long-term survival after radiofrequency ablation of unresectable hepatocellular carcinoma in patients with cirrhosisChandrajit P Raut
Department of Surgical Oncology, The University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 444, Houston, Texas, 77030-4009, USA
Ann Surg Oncol 12:616-28. 2005..RFA can be performed in these patients with relatively low complication rates. Confirmation of these results in randomized trials should be considered... - Surgical resection after downsizing of colorectal liver metastasis in the era of bevacizumabLee M Ellis
Department of Surgical Oncology, The University of Texas M.D. Anderson Cancer Center, Houston, TX, USA
J Clin Oncol 23:4853-5. 2005 - Expression and regulation of the novel vascular endothelial growth factor receptor neuropilin-1 by epidermal growth factor in human pancreatic carcinomaAlexander A Parikh
Department of Surgical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030, USA
Cancer 98:720-9. 2003..NRP-1 may act as a coreceptor for VEGF in pancreatic carcinoma, as it does in other tumor systems, thereby enhancing angiogenesis and the effect of VEGF on the growth of pancreatic adenocarcinoma... - Bevacizumab improves pathologic response and protects against hepatic injury in patients treated with oxaliplatin-based chemotherapy for colorectal liver metastasesDario Ribero
Department of Surgical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
Cancer 110:2761-7. 2007..The current study evaluated the effect of bevacizumab added to fluoropyrimidine-plus-oxaliplatin (5FU/OX) chemotherapy for colorectal liver metastases (CLM) on the pathologic response and nontumorous liver histology... - Future directions in the treatment of neuroendocrine tumors: consensus report of the National Cancer Institute Neuroendocrine Tumor clinical trials planning meetingMatthew H Kulke
Dana Farber Cancer Institute and Harvard Medical School, Boston, MA, USA
J Clin Oncol 29:934-43. 2011.... - The previously undescribed ZKSCAN3 (ZNF306) is a novel "driver" of colorectal cancer progressionLin Yang
Department of Cancer Biology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
Cancer Res 68:4321-30. 2008..Thus, the hitherto uncharacterized ZKSCAN3 adds to an expanding set of encoded products contributing to the progression of colorectal cancer... - Clinical and in vitro studies of imatinib in advanced carcinoid tumorsJames C Yao
Department of Gastrointestinal Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
Clin Cancer Res 13:234-40. 2007..Effective systemic therapy options for carcinoid tumors are lacking. We conducted in vitro studies and a phase II clinical trial to explore the activity of imatinib in carcinoid tumors... - Predicting the node-negative mesorectum after preoperative chemoradiation for locally advanced rectal carcinomaIsabelle Bedrosian
Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA
J Gastrointest Surg 8:56-62; discussion 62-3. 2004..Despite a substantial reduction in tumor volume with neoadjuvant CRT, local excision should be recommended with caution in patients with locally advanced rectal cancer... - Targeting angiogenesis driven by vascular endothelial growth factors using antibody-based therapiesAxel Grothey
Department of Oncology, Mayo Clinic Rochester, Rochester, Minnesota, USA
Cancer J 14:170-7. 2008.... - Overview of anti-VEGF therapy and angiogenesis. Part 1: Angiogenesis inhibition in solid tumor malignanciesLee M Ellis
John Wayne Cancer Institute, Santa Monica, CA, USA
Clin Adv Hematol Oncol 4:suppl 1-10; quz 11-2. 2006..These other issues, including the biologic rationale for anti-VEGF therapy, as well as recent clinical trial data with anti-VEGF agents in colorectal, pancreatic, lung, kidney, and brease cancers, are discussed... - Can inhibition of angiogenic pathways increase the efficacy of intravenous 5-fluorouracil-based regimens?Fairooz F Kabbinavar
Division of Hematology Oncology, Department of Medicine, 10945 Le Conte Ave, University of California Los Angeles 2338 John, PVUB MC, 718707, Los Angeles, CA 90095 7187, USA
Clin Colorectal Cancer 4:S69-73. 2004..The current study indicates that subpopulations of patients with advanced age or poor performance status could be treated successfully with 5-FU/LV in combination with bevacizumab without excessive toxicities... - Inhibition of integrin alpha5beta1 function with a small peptide (ATN-161) plus continuous 5-FU infusion reduces colorectal liver metastases and improves survival in miceOliver Stoeltzing
Department of Cancer Biology, The University of Texas M.D. Anderson Cancer Center, Houston 77030-4009, USA
Int J Cancer 104:496-503. 2003..The enhancement of antineoplastic activity from the combination of anti-angiogenic therapy and chemotherapy may be a promising approach for treating metastatic colorectal cancer... - A targeted approach for antiangiogenic therapy of metastatic human colon cancerLee M Ellis
Department of Cancer Biology and Surgical Oncology, The University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Boulevard, 444 Houston, Texas 77030-4009, USA
Am Surg 69:3-10. 2003..These angiogenic mediators thus serve as targets for therapy of metastatic colon cancer and have shown promise in preclinical trials... - Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesisDaniel J Hicklin
Department of Experimental Therapeutics, ImClone Systems Incorporated, New York, NY 10014, USA
J Clin Oncol 23:1011-27. 2005.... - The vascular endothelial growth factor family and its receptorsAlexander A Parikh
Department of Surgery Surgical Oncology, Temple University School of Medicine, Fourth Floor, Parkinson Pavilion, 3401 North Broad Street, Philadelphia, PA 19140, USA
Hematol Oncol Clin North Am 18:951-71, vii. 2004..A thorough understanding of the VEGF system is paramount in optimizing antiangiogenic therapies as a component of antineoplastic regimens... - Antiangiogenic therapy: more promise and, yet again, more questionsLee M Ellis
J Clin Oncol 21:3897-9. 2003 - Mammalian target of rapamycin is activated in human gastric cancer and serves as a target for therapy in an experimental modelSven A Lang
Department of Surgery, University of Regensburg, Medical Center, Regensburg, Germany
Int J Cancer 120:1803-10. 2007..In conclusion, mTOR is frequently activated in human gastric cancer and represents a promising new molecular target for therapy... - The angiogenic switch of human colon cancer occurs simultaneous to initiation of invasionYutaka Takahashi
Department of Surgical Oncology, Cancer Research Institute, Kanazawa University, Japan
Oncol Rep 10:9-13. 2003..These results suggest that angiogenic switch may occur between Tis and T1, i.e. simultaneous to initiation of invasion, in the early development of colon cancer... - Current overview of angiogenesis inhibitorsLee M Ellis
Surgical Oncology and Cancer Biology, University of Texas M. D. Anderson Cancer Center, TX, USA
Clin Adv Hematol Oncol 2:494-6, 520. 2004
Research Grants
- TRAINING OF ACADEMIC SURGICAL ONCOLOGISTSLee Ellis; Fiscal Year: 2007..As a result, this is a highly stimulating environment in which aspiring academic surgical oncologists can receive research training under the aegis of the T32 program. ..
- Function of VEGF Receptor-1 on Colorectal Cancer CellsLee Ellis; Fiscal Year: 2009..In addition, it is possible that VEGFR-1 expression on CRC cells may serve as a "predictive factor" for anti-VEGF/receptor containing anti-neoplastic regimens. ..